PRESENTATION

Q2 2024 — Presentation

Q2 2024PDF · 31 pages2.1 MB
Merck
Q2 2024 Earnings
July 30, 2024

-- 1 of 31 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 31 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward
health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 31 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 31 --

Delivered on our key strategic priorities in Q2 2024
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to augment pipeline
Created long-term value for patients
and shareholders
5

-- 5 of 31 --

Drove innovation and productivity through integration of data,
digital and analytics
Reached more people globally with our medicines and vaccines
Expanded and evolved our pipeline to drive future innovations
for patients
Significant progress over the past three years
6

-- 6 of 31 --

20,000
30,000
40,000
50,000
60,000
70,000
2022 	2023 	2024
Strong Q2 sales1 and earnings performance
7
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude charges for certain upfront payments related to collaborations and licensing agreements, or
charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Second quarter of 2023 includes $4.02 per share of such charges.
Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $0.77, $6.21 and $0.22 per share of such charges, respectively. 3. GAAP EPS $2.14.
$16.1B
+7%
+11% ex-Exchange
Q2 Worldwide Sales
Q2 Non-GAAP EPS3
$5.37
Full Year Sales
Full Year Non-GAAP EPS2
$59.3B
+22%
$60.1B
+1%
2022 	2023 	2024
$1.51
$7.48
GUIDANCE RANGE
$63.4B - $64.4B
+5% - +7%
GUIDANCE RANGE
$7.94 - $8.04
$2.28

-- 7 of 31 --

Advancing our broad pipeline
8
Vaccines	Cardiometabolic 	Oncology
Successful initial
launch following U.S.
approval, and received
positive CHMP opinion
Recent FDA approval
and unanimous ACIP
recommendation in
certain adult populations
Diverse Portfolio
& Pipeline
Presented data for
multiple novel
candidates at ASCO

-- 8 of 31 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 31 --

Strong Q2 worldwide sales growth
10
Merck
WORLDWIDE SALES1,2
$16.1B+7% growth
+11% ex-exchange3
$14.4B
+7% growth
+11% ex-exchange3
Human Health
$1.5B
+2% growth
+6% ex-exchange3
Animal Health
1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue.
3. ~2 percentage points of the negative impact of foreign exchange for Worldwide Sales and Human Health, and ~3 percentage points of the negative impact of foreign exchange
for Animal Health, was due to devaluation of the Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 10 of 31 --

Oncology: KEYTRUDA continues to drive excellent growth
11	Growth rates exclude the impact of foreign exchange.
1. ~4 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.
• KEYTRUDA sales of $7.3B increased 21%1
year-over-year, driven by uptake in earlier
stage cancers and continued strong global
demand from metastatic indications
– In the U.S., increase reflects uptake from KN-671
and KN-091 in NSCLC, as well as uptake from
KN-A39 in advanced urothelial cancer
– Ex-U.S. growth reflects continued uptake in
earlier stage cancers, including high-risk early-
stage TNBC and adjuvant RCC, as well as demand
from metastatic indications
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
2Q22 	2Q23 	2Q24
$5.3B
+30%
$6.3B
+21%
$7.3B
+21%

-- 11 of 31 --

Oncology: Strong performance across broad portfolio
• Lynparza 1 sales grew 4%, driven primarily by
higher demand in the U.S. and certain
international markets
• Lenvima 2 sales grew 4%, driven primarily by
higher demand in the U.S.
• WELIREG sales more than doubled, driven
by increased uptake in certain patients with
previously treated advanced RCC
$181M
+15%
$151M
+57%
12	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
2Q22 	2Q23 	2Q24
$310M
+15%
$275M
+17%
$317M
+4%
2Q22 	2Q23 	2Q24
$242M
+6%
$231M
+33%
$249M
+4%
2Q22 	2Q23 	2Q24
$50M
+89%
$27M
$126M
+150%

-- 12 of 31 --

2Q22 	2Q23 	2Q24
$1.7B
+40%
2Q22 	2Q23 	2Q24
$1.7B
+40%
$2.5B
+53%
Vaccines: Growth driven by GARDASIL and VAXNEUVANCE
13
• GARDASIL sales of $2.5B increased 4%
year-over-year
– In the U.S., sales benefitted from price,
demand and favorable CDC purchasing
patterns
– Ex-U.S., sales were driven by higher demand
across several markets, partially offset by
timing of shipments in China
• VAXNEUVANCE grew to $189M, driven
by ongoing launches in ex-U.S. markets
Growth rates exclude the impact of foreign exchange.
$2.5B
+4%
$1.7B
+40%
$12M
$168M $189M
+16%

-- 13 of 31 --

Cardiovascular: Successful initial launch of WINREVAIR
14
$1.7B
+40%
$1.9B
+27%
$2.5B
+4%
Sales of $70M1
Payors
 
Prescribers
 
Patients
• 	Many payors established coverage policies consistent with the label and
STELLAR criteria
• 	Other payors are in the process of developing policies
• 	>2,000 patients prescribed in the quarter
• 	Across all prescriptions, ~75-80% of patients receive commercial product
• 	>1,000 patients started treatment in the quarter, largely reflecting
prescriptions written in April and May
• 	Takes ~1 month on average for patients to start therapy
• 	>500 physicians have written at least one prescription
• 	Many prescribers are looking to gain experience with the product as they
prioritize patients who are in greatest need of additional therapy
• 	Most prescribers are from large academic centers or larger private practices
1. ~40% of sales were attributed to doses administered to patients, with the remainder due to distributors building inventory in support of increasing demand.

-- 14 of 31 --

Animal Health: Growth driven by livestock
15
• Animal Health sales increased 6% 1 to $1.5B
– Livestock sales grew 11%, driven by higher
demand for poultry and ruminant products, as
well as price
– Companion Animal growth reflects price,
partially offset by reduction in distributor
inventory
2Q22 	2Q23 	2Q24
$1.5B
+5%
$1.5B
+2%
$1.5B
+6%
Growth rates exclude the impact of foreign exchange.
1. ~3 percentage point negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 15 of 31 --

Q2 2024 non-GAAP financial results summary1
Q2 2024 	Q2 2023 	Change Change
Ex-FX
Sales 	$16.1 	$15.0 	+7% 	+11%
Non-GAAP Gross Margin 	80.9% 	76.6% 	+4.3pts 	+4.3pts
Non-GAAP Operating
Expenses $6.2 	$15.9 	-61% 	-61%
Non-GAAP Tax Rate 	14.1% 	-18.4% 	+32.5pts 	N/A
Non-GAAP Earnings /
(Loss) Per Share2,3 	$2.28 	($2.06) 	N/M 	N/M
$ in billions, except EPS amounts
16
1. Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other
metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should
be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached
to the earnings release. 2. Q2 2023 includes a charge of $10.2 billion, or $4.02 negative EPS impact, for the acquisition of Prometheus Biosciences. 3. Q2 2024 GAAP EPS of $2.14.

-- 16 of 31 --

Updated 2024 financial outlook
1. Guidance does not assume any additional significant potential business development transactions.
17
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$63.1B to $64.3B 	$63.4B to $64.4B • 	Assumes ~3 percentage point FX headwind
• 	Implies growth of 5% to 7%
Non-GAAP
Gross Margin Rate ~81.0% 	~81.0%
Non-GAAP
Operating Expenses1 	$25.2B to $26.1B 	$26.8B to $27.6B • 	Includes incremental $1.5B of charges related to EyeBio
acquisition and advancing assets, as well as investments in
progressing innovative pipeline
Other (Income) / Expense 	~$250M of expense 	~$350M of expense • 	Includes financing costs for the acquisitions of EyeBio and
Elanco’s aqua business
Tax Rate 	~14.5% to 15.5% 	~15.5% to 16.5% • 	Includes unfavorable impact from the non-tax deductible
upfront charge related to acquisition of EyeBio
Shares Outstanding 	~2.55B 	~2.54B 	• 	Assumes modest share repurchase
Non-GAAP EPS 	$8.53 to $8.65 	$7.94 to $8.04
• 	Includes one-time ~$0.51 charge related to EyeBio
acquisition, as well as ~$0.09 to finance EyeBio and Elanco
aqua business acquisitions and advance the acquired assets
• 	Assumes more than $0.30 FX headwind in 2024

-- 17 of 31 --

Key modeling considerations
CAPVAXIVE
GARDASIL
• 	Received FDA approval and ACIP recommendation
• 	Commercial uptake will be enabled by milestones such as MMWR publication, which typically lags
ACIP recommendation by a few months, as well as payor coverage and customer contracting
18
• 	Benefitted from extremely strong demand of GARDASIL in China over the past few years
• 	In 2Q there was a significant step down in shipments from Zhifei to points of vaccination compared
to prior quarters, resulting in higher inventory levels at Zhifei
• 	If shipments from Zhifei do not increase, it is likely that we will ship less than our full year 2024
contracted doses1 by the end of this year
• 	Opportunity in China remains very attractive as there are >120M females in the addressable
population living in Tier 1-5 cities have not yet received an HPV vaccination
WINREVAIR
• 	Received CHMP opinion and anticipate EMA approval in the coming months
• 	Reimbursement should occur in 2025 in most major markets, but expect Germany will receive
reimbursement and launch this year
1. Contracted doses in 2024 are less than the doses that were shipped in 2023

-- 18 of 31 --

19
Continue to invest in the
pipeline and business while
augmenting the pipeline
with value-enhancing
business development
$3.0
$0.7
$2.0
$0.2 $0.3
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Q2 Spend ($ in billions)
1. 	Reflects quarter spend
2. 	Reflects R&D excluding Business Development
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
2

-- 19 of 31 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 31 --

Important progress across our immunization programs
21
Pneumococcal 	RSV
• 	Received FDA approval for CAPVAXIVE, a 21-valent
pneumococcal conjugate vaccine for adults, as well as
unanimous ACIP recommendation for certain adult
populations
• 	First approved pneumococcal conjugate vaccine
specifically designed to cover serotypes responsible for
~85% of incidence of invasive pneumococcal disease in
individuals 65 years and older 1
• 	Currently under review by EMA
• 	Announced positive topline results from Phase 2b/3
trial evaluating clesrovimab, an investigational RSV
preventative monoclonal antibody for infants
• 	Study met primary efficacy and safety endpoints, as
well as secondary endpoint regarding RSV-associated
hospitalization
• 	Potential to provide a single, fixed-dose option to help
protect healthy and high-risk infants from birth
through their first full RSV season
1. According to CDC data from 2018-2021

-- 21 of 31 --

Executing upon our oncology development strategy
22
Immuno-oncology
Boost anti-tumor immune
responses
Precision Molecular
Targeting
Impact pathways that can drive
cancer growth
Tissue Targeting
Increase cancer cell sensitivity
with ADCs and immune-
engagers

-- 22 of 31 --

Continuing to harness the power of immuno-oncology
23
Recent KEYTRUDA Updates
• 	KEYNOTE-868: FDA approved KEYTRUDA in
combination with chemotherapy for treatment of
primary advanced or recurrent endometrial cancer
regardless of mismatch repair status
• 	KEYNOTE-522: Announced study demonstrated OS
benefit in patients with high-risk early-stage TNBC
• 	KEYNOTE-811: Announced study met OS dual primary
endpoint for treatment of 1L HER2-positive advanced
gastric or GEJ adenocarcinoma
• 	KEYNOTE-483: FDA granted priority review for
KEYTRUDA in combination with chemotherapy for 1L
treatment of unresectable advanced or metastatic
malignant pleural mesothelioma (PDUFA September 25,
2024)
Total:
40 approvals1 in distinct
indications
25 studies with OS benefit
Earlier Stage:
9 approvals1 in distinct
indications
4 studies with OS benefit
1. Represents approvals in the U.S.

-- 23 of 31 --

24
Updates across precision and tissue targeting
Precision Molecular Targeting 	Tissue Targeting
• Exercised option to advance opevesostat1 , an oral
nonsteroidal CYP11A1 inhibitor
• Two ongoing Phase 3 trials, OMAHA-1 and
OMAHA-2, evaluating opevesostat1 in
combination with hormone replacement therapy
for treatment of certain patients with metastatic
prostate cancer
• Received positive CHMP opinion for KEYTRUDA
in combination with Padcev for 1L treatment of
patients with unresectable or metastatic
urothelial carcinoma based on KN-A39/EV-3022
• FDA issued a Complete Response Letter for BLA
for patritumab deruxtecan3 for treatment of
certain adult patients with locally advanced or
metastatic EGFR-mutated NSCLC previously
treated with two or more systemic therapies
1. In collaboration with Orion 2. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 3. In collaboration with Daiichi Sankyo

-- 24 of 31 --

Ophthalmology
• Completed acquisition of EyeBio
• Restoret 	/MK-3000 is an investigational,
potentially first-in-class tetravalent tri-specific
Wnt antibody for treatment of diabetic
macular edema and neovascular age-related
macular degeneration
25
Important developments across our diverse pipeline
Cardiometabolic
• Received positive CHMP opinion for WINREVAIR
for treatment of PAH
• Anticipate European Commission decision on
marketing authorization application in 3Q 2024
Restoret 	/MK-30001:

-- 25 of 31 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 26 of 31 --

Appendix
27

-- 27 of 31 --

Q2 2024 GAAP financial results summary
28
Q2 2024 	Q2 2023 	Change 	Change Ex-FX
Sales 	$16.1 	$15.0 	+7% 	+11%
Operating Expenses1 $6.2 	$16.0 	-61% 	-60%
Tax Rate 	9.1% 	-11.9% 	-21.0pts 	N/A
GAAP Earnings /
(Loss) per Share1 $2.14 	($2.35) 	N/M 	N/M
$ in billions, EPS amounts
1. 2Q23 GAAP results include $10.2 billion charge or $4.02 per share for the acquisition of Prometheus Biosciences

-- 28 of 31 --

$11.4
$3.5
$7.6 $7.0
$1.2
$0
$3
$6
$9
$12
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 19B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$11B in the U.S.
Billions
Over the past 12 months
Capital investments
2024 to 2028
Commitment to the dividend
29
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
Order of priority
1. 	Reflects R&D excluding Business Development
2. 	Includes BD payments reflected in operating cash flow
3. 	Updated October 29, 2024: Previous values corrected by the company
2
1
E

-- 29 of 31 --

Driving value for patients and shareholders by progressing our pipeline
Key regulatory milestones since the last earnings call: 	Key data & clinical advancements since the last earnings call:
• 	In the U.S.:
o FDA accepted for priority review the sBLA for KEYTRUDA in combination
with chemotherapy as first-line treatment of patients with unresectable
advanced or metastatic malignant pleural mesothelioma based on
IND.227/KN-483
o FDA approved KEYTRUDA in combination with chemotherapy, followed by
KEYTRUDA as a single agent, for the treatment of adult patients with
primary advanced or recurrent endometrial carcinoma based on NRG-
GY018/KN-868
o FDA approved CAPVAXIVE for the prevention of invasive pneumococcal
disease and pneumococcal pneumonia in adults, and CDC’s ACIP
unanimously voted to recommend CAPVAXIVE as an option for certain
adults
• 	In the EU:
o Received positive CHMP opinion for KEYTRUDA in combination with
Padcev for the first-line treatment of adult patients with unresectable or
metastatic urothelial carcinoma based on KN-A39/EV-302 1
o Received positive CHMP opinion for WINREVAIR, in combination with
other PAH therapies, for the treatment of PAH in adult patients with
WHO FC II to III
• 	Presented data across broad oncology portfolio at ASCO,
including for KEYTRUDA (KN-966, KN-859, KN-A39, KN-671,
KN-224, KN-629), mRNA-4157/V940 2 (INT), vibostolimab
(anti-TIGIT), sacituzumab tirumotecan 3 (TROP2 ADC), and
patritumab deruxtecan 4 (HER3 ADC)
• 	Announced Phase 2b/3 trial evaluating clesrovimab (MK-1654)
met its primary safety and efficacy endpoints, including
reducing medically attended lower respiratory infections
(MALRI) caused by RSV through Day 150
• 	Announced Phase 3 KEYNOTE-811 and KEYNOTE-522 trials for
KEYTRUDA met overall survival endpoints
• 	Advanced our broad pipeline, initiating Phase 3 trials across
multiple candidates including sacituzumab tirumotecan 3 (MK-
2870, TROP2 ADC), enlicitide decanoate (MK-0616, PCSK9
inhibitor), and tulisokibart (MK-7240, TL1A inhibitor)
30
1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. In collaboration with Moderna
3. In collaboration with Kelun-Biotech 4. In collaboration with Daiichi Sankyo

-- 30 of 31 --

Broad and innovative pipeline to address significant unmet medical needs
Phase 2 	Phase 3 	Under regulatory review
V181
Dengue Virus
Vaccines
Infectious disease
MK-8189 4
Schizophrenia
Neuroscience
MK-8527
HIV-1 prevention
MK-8591B (islatravir+MK-8507)1
HIV-1 infection
MK-8591D (islatravir+lenacapavir)2,11
HIV-1 infection
MK-2060
Thrombosis
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
NASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due to Left
Heart Disease
Cardiometabolic
MK-4280A
(favezelimab+pembroliz
umab)
Bladder
cSCC
Endometrial
Esophageal
Melanoma
RCC
MK-5890 (boserolimab)
Neoplasm Malignant
MK-5909 (raludotatug
deruxtecan)6
Ovarian
LYNPARZA (MK-7339)8
Advanced Solid Tumors
LENVIMA (MK-7902)9
HNSCC
MK-2870 (sacituzumab
tirumotecan)7
Biliary
CRC
Neoplasm Malignant
Pancreatic
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab +
hyaluronidase)
cSCC
MK-4280
(favezelimab)
NSCLC
WELIREG (MK-6482)
Endometrial
Esophageal
HCC
Prostate
Rare Cancers
MK-7684A
(vibostolimab
+pembrolizumab)
Bladder
CRC
Endometrial
Melanoma
Ovarian
Prostate
RCC
V940 10
Bladder
cSCC
RCC
MK-1022 (patritumab
deruxtecan)6
Gastric
HNSCC
Melanoma
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
MK-2140 (zilovertamab
vedotin)
Hematological
Malignancies
MK-2400 (ifinatamab
deruxtecan)6
Bladder
CRC
Endometrial
HNSCC
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023	
6 In collaboration with Daiichi Sankyo 7In collaboration with Kelun-Biotech 8 In collaboration with AstraZeneca 9 In collaboration with Eisai	
10In collaboration with Moderna 11In collaboration with Gilead 12Developed under an agreement with Ridgeback Bio 13 In collaboration with Orion
	14 FDA issued CRL in June 2024
MK-6194
Vitiligo
Immunology
Restoret 	/MK-3000
Diabetic macular edema
Ophthalmology
Oncology
Infectious disease
Oncology
MK-1022 (patritumab deruxtecan)6
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084
NSCLC
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2400 (ifinatamab deruxtecan)6
SCLC
MK-2870 (sacituzumab tirumotecan)7
Breast
Cervical
Gastric
Endometrial
NSCLC
MK-3543
(bomedemstat)
Myeloproliferative Disorders
KEYTRUDA (MK-3475)
CSCC (EU)
Hepatocellular (EU)
Ovarian
SCLC
MK-3475A (pembrolizumab
+hyaluronidase)
NSCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
MK-5684 (opevesostat)13
Prostate
LYNPARZA (MK-7339)8
NSCLC
SCLC
LENVIMA (MK-7902)9
Esophageal
Gastric
MK-7684A (vibostolimab
+pembrolizumab)
NSCLC
SCLC
V940 10
Melanoma
NSCLC
MK-8591A (doravirine+islatravir)2
HIV-1 Infection
Immunization
MK-1654 (clesrovimab)
Respiratory Syncytial Virus (RSV)
Cardiometabolic
MK-7240 (tulisokibart)
Ulcerative Colitis
Immunology
MK-0616 (enlicitide decanoate)
Hypercholesterolemia
LAGEVRIO (MK-4482)3,12
COVID-19 antiviral
Gefapixant (MK-7264)5
Cough (US)
General Medicine
As of July 30, 2024
Oncology
KEYTRUDA (MK-3475)
Resectable NSCLC (JPN)
1L Urothelial (EU, JPN)
Endometrial Carcinoma (EU, JPN)
Cervical (EU, JPN)
Mesothelioma (US, EU, JPN)
MK-1022 (patritumab deruxtecan)6, 14
NSCLC (US)
WELIREG (MK-6482)
Certain VHL tumors (EU)
Advanced RCC (EU, JPN)
WINREVAIR (MK-7962)
Pulmonary Arterial Hypertension (EU)
Cardiometabolic
Vaccines
CAPVAXIVE (V116)
Pneumococcal conjugate vaccine, adult (EU)

-- 31 of 31 --